Kinetics, Efficacy and Safety of IVIG-L in Hypogammaglobulinemia Patients
Status:
Completed
Trial end date:
2004-12-01
Target enrollment:
Participant gender:
Summary
The kinetics, efficacy and safety of a liquid intravenous immunoglobulin product, IVIG-L,
were studied in patients with hypogammaglobulinemia, who are regularly treated with
intravenous immunoglobulin substitution therapy.